A weekly summary of Novamind news and media, including the announcement of our uplisting to the OTCQB Market and much more.
September 7, 2021
Treating Trauma with Psychedelic-Assisted Psychotherapy
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Hannah Cross to discuss how psychedelic-assisted psychotherapy is used to treat trauma.
August 31, 2021
Treating Eating Disorders with Ketamine-Assisted Psychotherapy
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss how ketamine-assisted psychotherapy is used to treat eating disorders
Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com
Novamind Uplists to OTCQB Venture Market
We pleased to announce our common shares have been approved for trading under the ticker symbol “NVMDF” on the OTCQB® Venture Market, a U.S. trading platform operated by the OTC Markets Group, Inc.
“With this listing, we look forward to expanding Novamind’s presence in the U.S. and deepening our relationships with a broad base of institutional and retail investors.” said Yaron Conforti, CEO and Director.
September 9, 2021
Novamind to Present at H.C. Wainwright 23rd Annual Global Investment Conference
CEO and Director, Yaron Conforti, will present the Company’s business model focused on growing a national network of psychiatry clinics and clinical research sites to rapidly scale access to psychedelic medicine.
Learn more about the Conference and register to schedule a one-on-one meeting with Novamind’s management here.
September 8, 2021
The Worldview-Changing Drugs Poised to Go Mainstream
BBC Future covers the experience, culture and future of psychedelics and “what might follow if psychedelics become mainstream.” It’s a popular theme in this week’s roundup: what the world will look like after the psychedelic revolution. “Psychedelics offer something that few other things can: an experience well beyond what our everyday reality could conceive or expect.” With such life changing drugs and therapies becoming available, there’s no doubt the future will look a lot different.
Neurocognitive Effects of Ketamine for Depression Examined
This article delivers more positive news about ketamine and esketamine, which we currently use in our Cedar Psychiatry clinics. Learn more about how we use these powerful drugs here. “Use of ketamine and esketamine for their antidepressant effects does not seem to have harmful neurocognitive effects in individuals with treatment-resistant depression, according to a review published online Aug. 5 in the Harvard Review of Psychiatry.”
Psychedelic Treatments Are Here, But Doctors Aren’t Prepared
Rick Doblin and Jennifer Ouyang Altman lay out the potential risks of not having standardized psychedelic education for providers. It’s a problem that will arise as psychedelics continue to move into the mainstream. It’s one reason why education is such a big component of our mission to increase access to psychedelic medicine. On the Psychedelic Therapy Frontiers podcast, we cover topics across the spectrum from trip-sitting to treating trauma with psychedelic-assisted psychotherapy. Another way we’re helping address this issue is by creating psychedelic treatment protocols, sharing best-in-class techniques and procedures with the wider population. Learn more here.
Follow @novamind_inc on Instagram
For further information, email us:
[email protected]
Was this email forwarded to you?
Subscribe to our weekly newsletter
Tags: COMPASS PATHWAYS, CSE, Field Trip Health Ltd., ketamine, MDMA, Psychedelic, Psychedelic Therapy, psychedelics, smallcap, smallcaps, stocks